Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

Core Insights - Capricor Therapeutics announced new data from the Phase 3 HOPE-3 clinical trial of Deramiocel for Duchenne muscular dystrophy (DMD), highlighting its potential impact on patients' daily lives and long-term outcomes [1][3][5] Company Overview - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead product candidate currently in late-stage development for DMD [10] - The company has received multiple designations for Deramiocel, including Orphan Drug Designation from the U.S. FDA and EMA, and Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S. [9] Clinical Trial Results - The HOPE-3 trial results showed a significant reduction in myocardial fibrosis measured by late gadolinium enhancement (LGE) on cardiac MRI (p=0.022) [6] - In patients with baseline cardiomyopathy, Deramiocel demonstrated a 3.3 percentage-point improvement in left ventricular ejection fraction (LVEF) versus placebo (p=0.017) [6] - The Global Statistical Test (GST) composite endpoint indicated a statistically significant overall treatment benefit favoring Deramiocel (p=0.017) [6] - The Duchenne Video Assessment (DVA) showed approximately 83% slowing of disease progression compared to placebo (p=0.018) [6] Regulatory Status - The Biologics License Application (BLA) for Deramiocel is currently under FDA review, with a target action date of August 22, 2026 [3][5] Collaboration and Commercialization - Capricor has entered into an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan, pending regulatory approval [12]